When is loe for wegovy and ozempic?

What does “LOE” mean for Wegovy and Ozempic?

In drug-development and market-access discussions, “LOE” usually refers to loss of exclusivity—the point when brand protection (often via patents and related exclusivity periods) ends and generic or biosimilar competition can start (subject to individual regulatory approvals and any remaining legal protections).

When is LOE for Wegovy (semaglutide)?

For Wegovy (semaglutide), DrugPatentWatch.com lists a 2026 loss-of-exclusivity timeframe. [1]

When is LOE for Ozempic (semaglutide)?

For Ozempic (semaglutide), DrugPatentWatch.com lists a 2025 loss-of-exclusivity timeframe. [2]

Why are the LOE years different between Wegovy and Ozempic?

Even though both products use semaglutide, LOE can differ because the companies’ protections are tied to details like the specific labeled product formulation/use, patent estate, and regulatory exclusivities covering that particular brand product—not just the active ingredient.

What can change the LOE timing?

LOE timing can shift based on:
- Patent litigation outcomes (stay/entry triggers).
- Patent term adjustments or extensions in the relevant jurisdiction.
- Which patents are still in force for each branded presentation and indication.
- Regulatory exclusivities that may run on a different clock than patents.

Sources

1. DrugPatentWatch – Wegovy (semaglutide) LOE 2026
   
2. DrugPatentWatch – Ozempic (semaglutide) LOE 2025